Acceleron Pharma, Inc. is developing drugs that regulate tissue size and function based on the Growth and Differentiation Factors (GDF) family of molecules. GDFs are potent, naturally occurring molecules that play a key role in the growth and repair of various tissues. Acceleron is developing therapies based on GDF biology to target diseases that affect bone, muscle, vasculature, and fat.

The company’s IP estate includes over 100 patents covering most of the GDF receptors. The company has a major development deal with Celgene for all bone growth indications. Under the terms of this deal, Celgene is covering a significant percentage of development costs, plus substantial milestone payments, significant royalties and North American co-marketing rights.